Table 2.
Typical clinical trials targeting integrins
| Integrin subtype | Intervention/treatment | Disease type | Phase | Current status | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|
| α5β1 | Volociximab | Metastatic renal cell carcinoma | 2 | Terminated | NCT00100685 |
| Pancreatic cancer | 2 | Completed | NCT00401570 | ||
| Ovarian cancer, primary peritoneal cancer | 1/2 | Completed | NCT00635193 | ||
| α4β7 | Vedolizumab | Ulcerative colitis | 4 | Recruiting | NCT05481619 |
| Crohn’s disease; ulcerative colitis | Not applicable | Completed | NCT02862132 | ||
| Inflammatory bowel disease | Not applicable | Completed | NCT02712866 | ||
| Type 1 diabetes | 1 | Recruiting | NCT05281614 | ||
| αvβ1; αvβ3; αvβ6 | IDL-2965 oral capsule | Idiopathic pulmonary fibrosis | 1 | Terminated | NCT03949530 |
| αvβ6; αvβ1 | PLN-74809 | Idiopathic pulmonary fibrosis | 2 | Completed | NCT04072315 |
| αLβ2; α4β1 | 7HP349 | Solid tumor | 1 | Completed | NCT04508179 |